These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 24861794)

  • 1. Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
    Palareti G
    Semin Hematol; 2014 Apr; 51(2):102-11. PubMed ID: 24861794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
    Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
    Pritchard ER; Murillo JR; Putney D; Hobaugh EC
    J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.
    Sarma A; Giugliano RP
    Hosp Pract (1995); 2015; 43(5):258-67. PubMed ID: 26559852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery.
    Spyropoulos AC; Al-Badri A; Sherwood MW; Douketis JD
    J Thromb Haemost; 2016 May; 14(5):875-85. PubMed ID: 26988871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bleeding during anti-vitamin K treatment. Incidence, risk factors and comparison with the new oral anticoagulants].
    Korin J
    Medicina (B Aires); 2012; 72(5):419-24. PubMed ID: 23089119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?
    Cohen AT; Granziera S; Veronese N; Zoppellaro G
    Semin Respir Crit Care Med; 2017 Feb; 38(1):29-39. PubMed ID: 28208196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants in patients with cancer.
    Bossaer JB; Covert KL
    Am J Health Syst Pharm; 2019 Jul; 76(14):1019-1027. PubMed ID: 31361880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease.
    Kampouraki E; Kamali F
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):789-797. PubMed ID: 28635328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of bleeding complications in patients with cancer on DOACs.
    Schulman S; Shrum J; Majeed A
    Thromb Res; 2016 Apr; 140 Suppl 1():S142-7. PubMed ID: 27067968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis.
    Nagata N; Yasunaga H; Matsui H; Fushimi K; Watanabe K; Akiyama J; Uemura N; Niikura R
    Gut; 2018 Oct; 67(10):1805-1812. PubMed ID: 28874418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants (DOAC) - Management of emergency situations.
    Lindhoff-Last E
    Hamostaseologie; 2017; 37(4):257-266. PubMed ID: 29582928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
    Adam SS; McDuffie JR; Ortel TL; Williams JW
    Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.